Filter by content type
Filter by year
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
January 4, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023 - … rationale builds on safety and efficacy data from the CLASSICAL-Lung study of pepinemab and avelumab and the observation that … rationale builds on safety and efficacy data from the CLASSICAL-Lung study of pepinemab and avelumab and the …
Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer
October 6, 2016 - … Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer … Vaccinex Announces Clinical Collaboration with … Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Vaccinex Announces Clinical Collaboration with … Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer 10/06/16 General Rochester, New York, October 6, …
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 - … The trial rationale builds on safety and efficacy of the CLASSICAL-Lung study of pepinemab and avelumab in lung cancer and the … The trial rationale builds on safety and efficacy of the CLASSICAL-Lung study of pepinemab and avelumab in lung cancer …
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
May 16, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup expenses … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup …
Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 24, 2019 - … inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) as well as the continuing progress of … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in … inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) as well as the continuing progress of …
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
August 15, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies phase 2 trials, partially offset by … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies phase 2 trials, partially …
Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based …
Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting
November 15, 2018 - … trial in combination with avelumab for non-small cell lung cancer, a Phase 1 study in combination with nivolumab or … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based … trial in combination with avelumab for non-small cell lung cancer, a Phase 1 study in combination with nivolumab or …
Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018
October 23, 2018 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based …
Pagination
- Previous page
- Page 4
- Next page